Core Alternative Capital Has $5.33 Million Stock Holdings in Medtronic PLC $MDT

Core Alternative Capital raised its stake in Medtronic PLC (NYSE:MDT) by 35.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 55,911 shares of the medical technology company’s stock after purchasing an additional 14,736 shares during the period. Medtronic accounts for approximately 1.5% of Core Alternative Capital’s investment portfolio, making the stock its 20th biggest position. Core Alternative Capital’s holdings in Medtronic were worth $5,325,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Riverbend Wealth Management LLC raised its holdings in Medtronic by 3.2% in the 3rd quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after acquiring an additional 107 shares during the period. Wynn Capital LLC lifted its holdings in Medtronic by 2.4% during the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock worth $442,000 after purchasing an additional 110 shares during the last quarter. Meridian Investment Counsel Inc. lifted its holdings in Medtronic by 0.4% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock worth $2,692,000 after purchasing an additional 110 shares during the last quarter. Saxony Capital Management LLC boosted its stake in Medtronic by 3.8% in the 3rd quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock valued at $290,000 after purchasing an additional 112 shares during the period. Finally, Cape Investment Advisory Inc. grew its holdings in Medtronic by 3.2% in the 2nd quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock valued at $314,000 after buying an additional 113 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

Medtronic Price Performance

Shares of MDT stock opened at $100.71 on Wednesday. The business has a fifty day simple moving average of $99.52 and a 200 day simple moving average of $95.48. The company has a market cap of $129.12 billion, a P/E ratio of 27.15, a P/E/G ratio of 2.65 and a beta of 0.71. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the previous year, the firm earned $1.26 earnings per share. The business’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is presently 76.55%.

Wall Street Analysts Forecast Growth

MDT has been the subject of a number of recent research reports. Daiwa Capital Markets boosted their target price on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. JPMorgan Chase & Co. boosted their price objective on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a report on Friday, November 14th. UBS Group lifted their price target on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research report on Wednesday, November 19th. Finally, Citigroup boosted their price target on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Fourteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).